



The Gut Microbiome as a Target for the Treatment of Inflammatory Bowel Diseases

Guest Editors:

Dr. Limin Shi

Medicine-Endocrinology and Metabolism Department, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA

Dr. Zhipeng Tao

Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76209, USA

Deadline for manuscript submissions:

25 May 2025

Message from the Guest Editors

Dear Colleagues,

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic and debilitating disorders characterized by chronic inflammation of the gastrointestinal tract. For a long time, these conditions were primarily viewed as immune-mediated disorders with genetic and environmental factors playing key roles. The exploration of the gut microbiome's role as a target for the treatment of inflammatory bowel diseases (IBDs) is a dynamic and rapidly evolving field that has gained significant attention over the past couple of decades. The topic continues to drive innovative research with the potential to revolutionize our understanding of IBD pathogenesis and treatment approaches.

The aim of this Special Issue is to present cutting-edge research and advancements in understanding the pivotal role of the gut microbiome in the treatment of inflammatory bowel diseases (IBDs). By assembling a collection of multidisciplinary research, we aim to provide a comprehensive overview of the potential therapeutic opportunities offered by harnessing the gut microbiome's intricate interactions with the host immune system.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)